Cargando…

Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TILs) as tumor-host antagonists

PURPOSE: To analyze the role of programmed death ligand 1 (PD-L1) immunohistochemisty in the context of tumor microenvironment in colon cancer (CC) with focus on the interaction between tumor budding and tumor-infiltrating lymphocytes (TILs) and to elucidate its potential value for immunooncologic t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lang-Schwarz, Corinna, Melcher, Balint, Hartmann, Arndt, Bertz, Simone, Dregelies, Theresa, Lang-Schwarz, Klaus, Vieth, Michael, Sterlacci, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505298/ https://www.ncbi.nlm.nih.gov/pubmed/34170390 http://dx.doi.org/10.1007/s00384-021-03985-9

Ejemplares similares

Adjuvant chemotherapy in stage II and III colon cancer: the role of the “budding and TILs-(tumor-infiltrating lymphocytes) combination” as tumor-host antagonists
por: Lang-Schwarz, Corinna, et al.
Publicado: (2021)

Helicobacter Infection and Gastric Adenoma
por: Bertz, Simone, et al.
Publicado: (2021)

Detection of Fusobacterium nucleatum in Patients with Colitis-Associated Colorectal Cancer
por: Dregelies, Theresa, et al.
Publicado: (2023)

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
por: Hall, MacLean, et al.
Publicado: (2016)

Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
por: Feng, Yong, et al.
Publicado: (2015)

Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs)
por: Nguyen, Linh T., et al.
Publicado: (2010)

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer
por: Poch, Michael, et al.
Publicado: (2018)

Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
por: Zhao, Yueshui, et al.
Publicado: (2022)

Cellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1(+) Subsets in Mouse Immunocompetent Models
por: Morales-Molina, Alvaro, et al.
Publicado: (2020)

Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes
por: Ni, Yunbi, et al.
Publicado: (2022)

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
por: Harter, Patrick N., et al.
Publicado: (2015)

PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells
por: Caraban, Bogdan Marian, et al.
Publicado: (2023)

Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential
por: Jiménez-Reinoso, Anaïs, et al.
Publicado: (2021)

Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer
por: Fanale, Daniele, et al.
Publicado: (2022)

Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma
por: Valentini, Davide, et al.
Publicado: (2018)

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
por: Kos, Zuzana, et al.
Publicado: (2020)

Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jie Qing, et al.
Publicado: (2013)

The frequency of dysplastic branching crypts in colorectal polypoid tubular adenomas
por: Rubio, Carlos A., et al.
Publicado: (2023)

Novel histological repertoire of crypt-associated anomalies in inflamed colon mucosa
por: Rubio, Carlos A, et al.
Publicado: (2023)

Correction: Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma
por: Valentini, Davide, et al.
Publicado: (2018)

Identification of the Tumor Infiltrating Lymphocytes (TILs) Landscape in Pure Squamous Cell Carcinoma of the Bladder
por: Eismann, Lennert, et al.
Publicado: (2022)

Identification of biomarkers related to Tumor-Infiltrating Lymphocytes (TILs) infiltration with gene co-expression network in colorectal cancer
por: Liao, Rong, et al.
Publicado: (2021)

Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jieqing, et al.
Publicado: (2014)

Correlation between cancer stem cells (CSCs) and tumor-infiltrating lymphocytes (TILs): do TILs interact with CSCs in non-small cell lung cancer?
por: Ling, Min, et al.
Publicado: (2020)

Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma
por: de Souza, Vinícius Gonçalves, et al.
Publicado: (2022)

Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer
por: Kashiwagi, Shinichiro, et al.
Publicado: (2017)

Enhanced tumor-infiltrating lymphocytes (eTIL) for cellular therapy of patients with pancreatic cancer or glioblastoma
por: Meng, Qingda, et al.
Publicado: (2015)

The Relationship between Tumor-infiltrating Lymphocytes (TILs) and Nasopharyngeal Carcinoma (NPC): A Systematic Review
por: Prasetyo, Awal, et al.
Publicado: (2021)

Evaluation of tumor-infiltrating lymphocytes (TILs) in molecular subtypes of an Indian cohort of breast cancer patients
por: Vaid, Pooja M., et al.
Publicado: (2022)

Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers
por: Tas, Liselotte, et al.
Publicado: (2023)

Clinical scale zinc finger nuclease (ZFN)-driven gene-editing of PD-1 in tumor infiltrating lymphocytes (TIL) for the potential treatment of metastatic melanoma
por: Beane, Joal D, et al.
Publicado: (2014)

Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist’s Perspective
por: Angelico, Giuseppe, et al.
Publicado: (2023)

Fewer tumour-specific PD-1(+)CD8(+) TILs in high-risk “Infiltrating” HPV(−) HNSCC
por: Xu, Ke, et al.
Publicado: (2020)

Resident Memory-Like Tumor-Infiltrating Lymphocytes (TIL(RM)): Latest Players in the Immuno-Oncology Repertoire
por: Smazynski, Julian, et al.
Publicado: (2018)

Fas Ligand (FasL) in Association with Tumor-Infiltrating Lymphocytes (TILs) in Early Stage Cervical Cancer
por: Anggraeni, Tricia Dewi, et al.
Publicado: (2020)

TilGAN: GAN for Facilitating Tumor-Infiltrating Lymphocyte Pathology Image Synthesis With Improved Image Classification
por: SAHA, MONJOY, et al.
Publicado: (2021)

Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints
por: Hudry, Delphine, et al.
Publicado: (2022)

Clinical Meaning of Stromal Tumor Infiltrating Lymphocytes (sTIL) in Early Luminal B Breast Cancer
por: García-Torralba, Esmeralda, et al.
Publicado: (2023)

Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer
por: Huertas-Caro, Carlos A., et al.
Publicado: (2023)

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome
por: Bekos, Christine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jg2js12ugilm184ndimb74deh9